Welcome to our dedicated page for Cbdmd SEC filings (Ticker: YCBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The cbdMD, Inc. (NYSE American: YCBD) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures from EDGAR with AI-supported summaries to help interpret key documents. cbdMD is a North Carolina corporation focused on hemp-derived cannabinoid products and related wellness brands, and its filings provide detailed insight into its operations, capital structure, and risk profile.
Investors can review annual reports on Form 10-K for discussions of cbdMD’s multi-brand business model spanning cbdMD, Paw CBD, ATRx Labs, and Herbal Oasis, along with risk factors, going concern language, and descriptions of its hemp-derived CBD and Delta-9 product lines. Quarterly reports on Form 10-Q offer interim financial statements and management discussion of sales trends, gross margins, and operating results.
cbdMD also files numerous current reports on Form 8-K that document material events. Recent 8-Ks describe preferred stock financings, the adoption of an equity compensation plan, regaining compliance with NYSE American listing standards, and the asset purchase of Gaia Botanicals, LLC, including the Bluebird Botanicals brand and online CBD marketplace. These filings outline terms of capital raises, equity designations, and key transaction details. Additional registration statements on Form S-1 and S-1/A cover resale registrations for shares issuable upon conversion of preferred stock and shares tied to an equity line of credit with an institutional investor.
On this page, AI-generated overviews can help explain complex sections of cbdMD’s 10-K and 10-Q filings, highlight significant items in 8-Ks, and summarize registration statements related to equity offerings. Users can also access information about equity compensation plans and preferred stock designations, and track any insider or significant shareholder activity reported in relevant forms. Combined, these SEC filings give a structured view of YCBD’s financial condition, financing arrangements, corporate governance, and strategic transactions, supporting deeper analysis of the company’s stock.
Porter Jeffrey H reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Jeffrey H. Porter reported receiving a grant of 1,572 restricted stock units of common stock on April 14, 2026 as compensation for his Board service. After this award, he directly holds 3,144 common shares and also controls sizable indirect holdings through several related entities.
Roe Kevin Charles reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Kevin Charles Roe received a grant of 1,572 restricted stock units, each representing a right to one share of common stock, as compensation for Board service under the company’s 2021 or 2025 Equity Compensation Plan.
The award was approved by the Compensation, Corporate Governance and Nominating Committee and carries a stated price of $0.00 per unit, reflecting its nature as equity compensation rather than a market purchase. The restricted stock units vest quarterly on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027. Following this grant, Roe directly holds 26,707 shares or share-equivalent units of cbdMD common stock.
Swift Sibyl Nichole reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Sibyl Nichole Swift received a grant of 1,572 shares of Common Stock on April 14, 2026 as an equity award, bringing her direct holdings to 4,145 shares. The award is in the form of restricted stock units, each representing a right to one share of common stock.
The restricted stock units were granted as compensation for her service on the Board of Directors under the company’s 2021 or 2025 Equity Compensation Plan. They vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, and were approved in advance by the Compensation, Corporate Governance and Nominating Committee.
Sellers Bakari T. reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Bakari T. Sellers reported an equity compensation grant of 1,572 shares of common stock in the form of restricted stock units at no cash cost per share. Following this award, his directly held equity position increased to 4,324 shares.
The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, aligning compensation with ongoing Board service under cbdMD’s 2021 or 2025 Equity Compensation Plan.
Stephen Scott G. reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Stephen Scott G. received a grant of 1,572 restricted stock units as compensation for serving on the Board of Directors. Each unit represents one share of common stock and will vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027. Following this award, he holds 4,412 shares of common stock directly.
Raines William F III reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director William F. Raines III received a grant of 1,572 restricted stock units, each representing one share of common stock, as compensation for his service on the board. The grant carried no cash purchase price.
The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, under the company’s 2021 or 2025 Equity Compensation Plan. Following this award, Raines holds 13,676 shares of the company’s common stock directly.
cbdMD, Inc. updated its director compensation program. On April 14, 2026, the board granted each independent director and the non-management employee director 1,572 restricted stock units (RSUs) under the 2025 Equity Compensation Plan for the term beginning March 31, 2026. These RSUs vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, with value based on the common stock closing price on April 14, 2026. The board also set annual cash fees, including a $35,000 retainer per independent director and additional amounts for the board chair and key committee roles.
cbdMD, Inc. reported that shareholders approved its 2025 Equity Compensation Plan, creating a new stock-based incentive program for employees, directors and consultants. The plan initially reserves 891,316 shares of common stock for options, restricted stock and other equity awards.
The plan includes an evergreen formula that can increase the share pool each year by 2% of shares outstanding on September 30, up to 300,000 shares annually. With shareholder approval, a previously contingent 445,000-share restricted stock award to CEO and CFO T. Ronan Kennedy became effective. At the 2026 annual meeting, 10,495,561 shares were entitled to vote and a quorum of 54.6% was reached, with all seven proposals approved.
cbdMD, Inc. registers 2,000,000 shares of common stock for resale by selling shareholders, consisting of shares issuable upon conversion of Series C Convertible Preferred Stock, assuming a $1.13 conversion price. The company will receive no proceeds from these resales. The filing states 10,495,561 shares of common stock outstanding as of February 19, 2026. The Series C Preferred Stock accrues dividends at 10% per annum and is subject to a 4.99% beneficial ownership limitation and an Exchange Cap that prevents issuance above 19.99% of outstanding common stock without shareholder approval.